https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Grants Birelentinib Fast Track Designation for Patients With Relapsed or Refractory CLL/SLL

FDA Grants Birelentinib Fast Track Designation for Patients With Relapsed or Refractory CLL/SLL

Birelentinib gains FDA fast track designation, offering hope for relapsed CLL/SLL patients resistant to current BTK and BCL-2 therapies.

administrator

Related Articles